Après AI, le Déluge

By KIM BELLARD I have to admit, I’ve steered away from writing about AI lately. There’s just so much going on, so fast, that I can’t keep up. Don’t ask me how GPT-5 differs from GPT-4, or what Gemini does versus Genie 3. I know Microsoft really, really wants me to use Copilot, but so…

Read More

What A Digital Health Doc Learned Recertifying His Boards

By JEAN LUC NEPTUNE I recently got the good news that I passed the board recertification exam for the American Board of Internal Medicine (ABIM). As a bit of background, ABIM is a national physician evaluation organization that certifies physicians practicing internal medicine and its subspecialties (every other specialty has its own board certification body…

Read More

Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Protagonist Therapeutics’ drug rusfertide reduced the need for phlebotomies as a way to treat the rare blood cancer polycythemia vera. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology. The post Shining Light on How Protagonist, Takeda Drug Brings Treatment of a…

Read More

Links

When is a public health problem a crisis?LA has the worst quality roads.CERN explained.IV fluid shortage.Too many 3-pointers.

Read More